ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "gender"

  • Abstract Number: 1062 • ACR Convergence 2025

    Sex-related differences in clinical presentation and patient-reported burden in chronic back pain: Are these findings specific to axSpA? Results from the SHERPAS Cohort

    Diego Benavent1, Mar Tapia2, Daniel Bernabeu2, Victor Muley2, Manuel Juárez3, Alejandro Balsa4, Chamaida Plasencia-Rodríguez4 and Victoria Navarro-Compan5, 1Hospital Universitari de Bellvitge, Madrid, Spain, 2HU La Paz, Madrid, Spain, 3Rheumatology Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, 4Hospital Universitario La Paz, Madrid, Spain, 5Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain

    Background/Purpose: Sex-related differences in axial spondyloarthritis (axSpA) have been described regarding clinical features, disease burden, and particularly patient-reported outcomes. These differences influence patient management, including…
  • Abstract Number: 1012 • ACR Convergence 2025

    Racial and Gender Disparities in Gout Clinical Trials

    Fizza Zulfiqar1, Dania Kaur2, Meaghan Bethea3, Taylor Spencer4, Samhitha Bitla5, Abhinav Vyas6 and Camelia Arsene7, 1Trinity Health Oakland/Wayne State University, Pontiac, MI, 2North Alabama Medical Center, Muscle Shoals, AL, 3Trinity Health Oakland Hopsital, Pontiac, MI, 4Trinity Health Oaklnd Hospital, Pontiac, MI, 5Trinity Health Oakland Hospital, Pontiac, MI, 6Vanderbilt University, Nashvile, TN, 7Trinity Health Oakland Hospital, Pontiac

    Background/Purpose: To develop effective novel treatment strategies for Gout disease that cater to patients from diverse backgrounds, it is crucial that all racial groups, without…
  • Abstract Number: 0719 • ACR Convergence 2025

    A Combined Transcriptomics and Proteomics Approach to Identify Immune Signatures in ANCA-Associated Glomerulonephritis

    Ivana Stojkic1, Arnon Arazi2, Huijuan Song3, Pearlly Yan3, Estela Puchulu-Campanella3, Hubao Wang3, Lynn Fussner3, Brad Rovin4, Stacy Ardoin1 and Salem Almaani3, 1Nationwide Children's Hospital, Columbus, OH, 2The Feinstein Institutes for Medical Research, Manhasset, 3OSU, Columbus, OH, 4The Ohio State University, Columbus, OH

    Background/Purpose: ANCA-associated vasculitis frequently involves the kidneys causing glomerulonephritis (AAGN). Despite advances in treatment, many patients develop end-stage kidney disease. An improved understanding of the…
  • Abstract Number: 2357 • ACR Convergence 2025

    Impact of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Active Psoriatic Arthritis: Key Subgroup Analyses in the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial

    Lihi Eder1, Iain McInnes2, Christopher Ritchlin3, Alexis Ogdie4, Arthur Kavanaugh5, Laura Coates6, Georg Schett7, Alan Kivitz8, Nuala Brennan9, Alex Godwood9, Matthew R. Thomas9, Eva Cullen9, Kristian Reich10, Joseph F Merola11 and Philip J. Mease12, 1University of Toronto, Toronto, ON, Canada, 2University of Glasgow, Glasgow, United Kingdom, 3University of Rochester Medical Center, Canandaigua, NY, 4University of Pennsylvania, Philadelphia, PA, 5University of California, San Diego, School of Medicine, San Diego, CA, 6Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, 7Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 8Altoona Center for Clinical Research, Duncansville, PA, 9MoonLake Immunotherapeutics AG, Zug, Switzerland, 10MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, 11Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, 12Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA

    Background/Purpose: PsA is a chronic inflammatory disease affecting heterogeneous tissues, with unmet need for therapies with robust efficacy across disease domains. Sonelokimab (SLK) is a…
  • Abstract Number: 0596 • ACR Convergence 2025

    Effect of Gender and Follow-up Time in Damage Accrual: Data from a Latin America Lupus Cohort

    Diana Fernandez1, Rosana Quintana2, Karen Roberts3, Romina Nieto2, Marina Scolnik4, Carmen Funes Soaje5, CINTIA OTADUY6, Veronica Saurit7, Valeria Arturi8, GUILLERMO ARIEL BERBOTTO9, Maria Constanza Bertolaccini10, Mario Eduardo Kerzberg11, Maria de los Angeles Gargiulo12, Cecilia Pisoni13, Ana Carolina Ralle14, Joaquín Martinez Serventi15, Ana Silva16, ODIRLEI MONTICIELO17, Henrique Mariz18, Laíssa Cristina Alves Alvino19, Eduardo Borba20, Emily Figueiredo Neves Yuki21, Edgard Torres dos Reis-Neto22, Iris Guerra Herrera23, Milena Mimica24, Gustavo Aroca-Martínez25, Antonio Iglesias-Gamarra26, Carlos Alberto Cañas27, Gerardo Quintana-Lopez28, Carlos Toro-Gutierrez29, Mario Moreno Alvarez30, Olga-Lidia Vera-Lastra31, Margarita Portela Hernández32, Hilda Fragoso-Loyo33, Luis H Silveira34, Yelitza Gonzalez Bello35, Carlos Abud-Mendoza36, Jorge Antonio Esquivel Valerio37, Marcelo Barrios38, Lourdes Carolina Vázquez39, Magaly Alva Linares40, Manuel Ugarte-Gil41, Armando Calvo42, Roberto Muñoz-Louis43, Ana Carina Pizzarossa44, Gonzalo Silveira45, Federico Zazzetti46, Ashley Orillion47, Urbano Sbarigia48 and Guillermo Pons-Estel2, 1Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, 2Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina, Rosario, Argentina, 3Consultora externa de GLADEL, Rosario, Argentina, Rosario, Argentina, 4Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, 5Hospital Italiano de Córdoba, Córdoba, Argentina, Cordoba, Argentina, 6Servicio de Reumatología Hospital Córdoba y Sanatorio Allende, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, Córdoba, Argentina, 7Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, 8Hospital San Martin de La Plata, La Plata, Argentina, La Plata, Argentina, 9Sanatorio Británico, Rosario, Argentina, ROSARIO, Argentina, 10Hospital Ángel C. Padilla, Tucumán, Argentina, Tucumán, Argentina, 11Hospital J.M Ramos Mejía, Buenos Aires, Argentina, CABA, Argentina, 12Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires; Buenos Aires, Argentina, Buenos Aires, Argentina, 13CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno”, Buenos Aires, Argentina, Ciudad Autonoma Buenos Aires, Argentina, 14Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, 15Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, Buenos Aires, Argentina, 16Hospital das Clinicas da Universidade Federal de Goias, Goiania, Brazil, Goiania, Brazil, 17Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, 18Universidad Federal de Pernambuco, Pernambuco, Brazil, Pernambuco, Brazil, 19Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio de Janeiro, Brazil, 20Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, 21Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, 22Universidad Federal São Paulo, São Paulo, Brazil, São Paulo, Brazil, 23Hospital del Salvador Santiago de Chile, Santiago, Chile, Santiago, Chile, 24Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, 25Clínica de la Costa y Universidad Simón Bolívar, Barranquilla, Colombia, barranquilla, Colombia, 26Universidad Nacional de Colombia, Barranquilla, Colombia, 27Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, 28Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, 29Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, 30Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, 31División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, CDMX, Mexico, Mexico City, Mexico, 32Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, 33Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, 34Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, 35Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Mexico, 36Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, San Luis Potosí, Mexico, 37Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, 38Hospital de Clínicas II, Uruguay, Uruguay, Uruguay, 39Facultad de Ciencias Médicas. Universidad Nacional de Asunción-Paraguay, Paraguay, Asunción, Paraguay, 40HOSPITAL EDGARDO REBAGLIATI MARTINS, San Borja, Peru, 41Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, 42Hospital Nacional Cayetano Heredia Universidad Peruana Cayetano Heredia, Lima, Peru, Jesús María, Peru, 43Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, 44Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, 45Facultad de Medicina - Universidad de la República, Montevideo, Uruguay, Montevideo, Uruguay, 46Johnson & Johnson, Horsham, PA, USA, Ambler, PA, 47Johnson & Johnson, Spring House, PA, USA, Spring House, PA, 48Johnson & Johnson, Beerse, Belgium

    Background/Purpose: Previous studies have shown that male gender is an independent predictor of organ damage in patients with systemic lupus erythematosus (SLE), particularly in the…
  • Abstract Number: 2356 • ACR Convergence 2025

    Clinical Efficacy in Male and Female Patients With Active Psoriatic Arthritis Treated With Deucravacitinib: A Pooled Analysis of Pivotal Phase 3 Studies

    Lihi Eder1, Philip J. Mease2, Joseph F Merola3, Alexis Ogdie4, Atul Deodhar5, Laura Coates6, Stefan Varga7, Navya Kalapala7, Ying-Ming Jou8, Eleni Vritzali9 and Laure Gossec10, 1University of Toronto, Toronto, ON, Canada, 2Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, 3Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, 4Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, 5Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 6Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, 7Bristol Myers Squibb, Princeton, NJ, 8Bristol Myers Squibb, Princeton, 9Bristol Myers Squibb, Boudry, Switzerland, 10Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France

    Background/Purpose: PsA affects male and female patients equally; however, variations in clinical manifestations and treatment responses between sexes have been reported. Deucravacitinib is an oral,…
  • Abstract Number: 0589 • ACR Convergence 2025

    Comparing Efficacy of Upadacitinib in Male and Female Patients with axSpA: Results from the SELECT-AXIS 1 and 2 Trials

    Sofia Ramiro1, Anna Molto2, Elena Nikiphorou3, Marcelo Pinheiro4, Jamie Urbanik5, Tianming Gao6, Shirley Chen7, Jayne Stigler8, Jessica A. Walsh9 and Lihi Eder10, 1Leiden University Medical Center, Bunde, Netherlands, 2Assistance Publique Hôpitauxde Paris, Paris, France, 3King's College London, London, United Kingdom, 4UNIFESP/ EPM, São Paulo, São Paulo, Brazil, 5AbbVie, Grayslake, IL, 6AbbVie, North Chicago, IL, 7AbbVie, Somerset, NJ, 8AbbVie, Round Lake, IL, 9Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, 10University of Toronto, Toronto, ON, Canada

    Background/Purpose: Evidence suggests that the treatment effectiveness of TNFis and IL-17is is higher in male (M) vs female (F) patients (pts) with axSpA.1,2 Data comparing…
  • Abstract Number: 2322 • ACR Convergence 2025

    Gender-related Differences in Peripheral and Axial Spondyloarthritis

    Mehmet Tuncay Duruöz1, Halise Hande Gezer1, İlknur Aktaş2, Servet Akar3, Nilay Şahin4, Özgür Akgül5, Sami Hizmetli6, Meltem Alkan Melikoğlu7, Umut Kalyoncu8, Erhan Çapkın9, fatma Gülçin Ural10, Figen Yılmaz11, Sebnem ATAMAN12 and İlhan Sezer13, 1Marmara University Medical School PMR Department, Rheumatology Division, Istanbul, Turkey, 2Istanbul Fatih Sultan Mehmet Training and Research Hospital, PMR, Turkey, Istanbul, Turkey, 3Department of Medicine, Izmir Katip Çelebi University School of Medicine, Izmir, Turkey, 4Balikesir University School of Medicine, PMR, Turkey, Balıkesir, Turkey, 5Manisa Celal Bayar University School of Medicine, Rheumatology, Turkey, Manisa, Turkey, 6Sivas Cumhuriyet University School of Medine, Rheumatology, Turkey, Sivas, Turkey, 7Erzurum Atatürk University School of Medicine, Rheumatology, Turkey, Erzurum, Turkey, 8Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, 9Karadeniz Teknik University School of Medicine, PMR, Turkey, Trabzon, Turkey, 10Ankara Yildirim Beyazit University School of Medicine, PMR, Turkey, Ankara, Turkey, 11Istanbul Sisli Etfal Training and Research Hospital, PMR, Turkey, Istanbul, Turkey, 12Ankara University School of Medicine, Rheumatology, Turkey, Ankara, Turkey, 13Akdeniz University School of Medicine, Rheumatology, Turkey, Antalya, Turkey

    Background/Purpose: This study sought to compare clinical characteristics between female and male patients with spondyloarthritis (SpA) in a Turkish population.Methods: This study included 489 peripheral…
  • Abstract Number: 0557 • ACR Convergence 2025

    Efficacy of Upadacitinib in Male and Female Patients with PsA: Results from the SELECT-PsA 1 and 2 Trials

    Lihi Eder1, Axel Hueber2, Lucia Novelli3, Tianming Gao3, Jayne Stigler4, Zhiyuan Du3, Rodrigo García Salinas5, Grace Wright6 and Sofia Ramiro7, 1University of Toronto, Toronto, ON, Canada, 2Klinikum Nuernberg, Nuernberg, Germany, 3AbbVie, North Chicago, IL, 4AbbVie, Round Lake, IL, 5Hospital Italiano La Plata, La Plata, Argentina, 6Grace C Wright MD PC, New York, NY, 7Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: Biologic sex can impact both clinical phenotype and therapeutic response in PsA.1–3 Previous studies have suggested that male patients (pts) may achieve better treatment…
  • Abstract Number: 2264 • ACR Convergence 2025

    Male Sex and Obesity Are Risk Factors for Sarcopenia in RA: Korea National Health and Nutrition Survey 2008–2011

    Yoon-Jeong Oh1, Jin-Wuk Hur2 and Chang-Nam Son3, 1Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu, Republic of Korea, 2Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Republic of Korea, 3UIJEONGBU EULJI MEDICAL CENTER, EULJI UNIVERSITY, UIJEONGBU, Republic of Korea

    Background/Purpose: Sarcopenia is a medical condition characterized by the progressive loss of skeletal muscle mass, strength, and function. It is primarily associated with aging, but…
  • Abstract Number: 0873 • ACR Convergence 2025

    Sex Differences in Proteomic Profiles and the Impact of Deucravacitinib Treatment in Patients with Active Psoriatic Arthritis: A Pooled Phase 3 Analysis

    Lihi Eder1, Shangzhong Li2, Philip J. Mease3, Christopher Ritchlin4, Walter P Maksymowych5, Hendrik Schulze-Koops6, Josef Smolen7, Oliver FitzGerald8, Vinod Chandran9, Chun Wu10 and Jinqi Liu2, 1University of Toronto, Toronto, ON, Canada, 2Bristol Myers Squibb, Princeton, NJ, 3Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, 4University of Rochester Medical Center, Canandaigua, NY, 5Department of Medicine, University of Alberta, Edmonton, AB, Canada, 6LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany, 7Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 8UCD, Dublin 6, Dublin, Ireland, 9Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, 10Bristol Myers Squibb, Princeton

    Background/Purpose: PsA affects male and female patients equally; however, variations in manifestations and treatment response exist between sexes. Deucravacitinib is an oral, selective, allosteric tyrosine…
  • Abstract Number: 2196 • ACR Convergence 2025

    Recognition and Treatment of Idiopathic Granulomatous Mastitis: A Case Series

    Jenny Solomon1, Julie Piccione1, Julie Nusbaum2, Steven Carsons3 and Gregg Blumberg1, 1NYU Langone Long Island, Mineola, 2NYU Langone Health, New York, NY, 3NYU Long Island School of Medicine, Mineola, NY

    Background/Purpose: Idiopathic Granulomatous Mastitis (IGM) is a rare benign inflammatory condition of the breast usually affecting women of childbearing age with a history of breastfeeding.…
  • Abstract Number: 0841 • ACR Convergence 2025

    Comparing the Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Outcomes in Lupus Nephritis: A Retrospective Cohort Study

    Kinga Grzybowski1 and Irene Tan2, 1Jefferson Einstein Montgomery Hospital, Maspeth, NY, 2Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA

    Background/Purpose: Lupus Nephritis (LN) is one of the most serious complications of SLE (Systemic Lupus Erythematosus) characterized by an attack of the kidneys by the…
  • Abstract Number: 0578 • ACR Convergence 2024

    Gender Differences in Disease Parameters, Adherence to Treat to Target Strategy and Outcomes in Axial Spondyloarthritis (axSpA) in Pakistani Cohort

    Muhammad Saeed1, HIna Ahmed2 and Aziza Ahmed3, and Arthritis Carte Foundation Faculty, 1Central Park Medical College, Arthritis Care Foundation, Lahore, Pakistan, 2Central Park Medical College, Lahore, Pakistan, 3Rashid Latif Medical College, Lahore, Pakistan

    Background/Purpose: In patients with Axial Spondyloarthritis (axSpA) there has been wide variability in terms of gender regarding disease characteristics as well as outcomes across different…
  • Abstract Number: 1708 • ACR Convergence 2024

    Unveiling the Uterine-Joint Axis: Dysbiosis and Subclinical Uterine Inflammation in Female Axial Spondyloarthritis Pathogenesis

    Daniele Mauro1, Matteo Vecellio2, Anne-Sophie Bergot3, Eva Schmid4, Giulio Forte5, Alessia Stingo6, Alessia Salzillo5, Aldo Pastore7, Paolo Aretini7, Francesca Di Lorenzo7, Antonio ciancio5, Ilenia Pantano5, Gabriele Saccone8, Fulvio Zullo9, carlo Maurizio Montecucco10, Aroldo Rizzo11, Georg Schett12, Ranjeny Thomas13, Mario Zaiss14 and Francesco Ciccia15, 1University of Campania, Italy, Naples, Naples, Italy, 2Fondazione Pisana per la Scienza ONLUS, Pisa, Italy, 3Frazer Institute, University of Queensland, Brisbane, Australia, 4Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Rheumatology and Immunology, Erlangen, Erlangen, Germany, 5University of Campania L. Vanvitelli, Naples, Italy, 6University of Campania L. Vanvitelli, Nasples, Italy, 7Fondazione Pisana per la Scienza ONLUS, Giuliano Terme, Italy, 8University Federico II of Naples, Naples, Italy, 9University of Catanzaro, Catanzaro, Italy, 10Unit of Rheumatology, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy, 11Azienda Ospedaliera Ospedali riuniti Villa Sofia Cervello,, Palermo, Italy, 12Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 13University of Queensland, Brisbane, Australia, 14Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universittsklinikum Erlangen, Erlangen, Germany; 2 Deutsches Zentrum für Immuntherapie (DZI), Erlangen, Germany, 15Università degli studi della Campania Luigi Vanvitelli, Naples, Italy

    Background/Purpose: Numerous studies exploring gender differences in axial spondyloarthritis (AxSpA) have noted that women exhibit distinct disease manifestations. Yet, a definitive pathophysiological distinction of these diverse…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology